Systematic review of 23 studies (975 patients) with hypersensitivity pneumonitis: pooled FVC% changes were non-significant for rituximab, azathioprine, MMF and corticosteroids; rituximab and MMF improved DLCO%. Evidence for pirfenidone and nintedanib came from single studies.
Meta-analysisn = 975
Nabeh et al. Beyond corticosteroids: A systematic review and meta-analysis of novel therapies for hypersensitivity pneumonitis